FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149731696> ?p ?o ?g. }

• W2149731696 endingPage "1172" @default.
• W2149731696 startingPage "1164" @default.
• W2149731696 abstract "Background In an open-label phase 1 trial, gene delivery of the trophic factor neurturin via an adeno-associated type-2 vector (AAV2) was well tolerated and seemed to improve motor function in patients with advanced Parkinson's disease. We aimed to assess the safety and efficacy of AAV2-neurturin in a double-blind, phase 2 randomised trial. Methods We did a multicentre, double-blind, sham-surgery controlled trial in patients with advanced Parkinson's disease. Patients were randomly assigned (2:1) by a central, computer generated, randomisation code to receive either AAV2-neurturin (5·4×1011 vector genomes) injected bilaterally into the putamen or sham surgery. All patients and study personnel with the exception of the neurosurgical team were masked to treatment assignment. The primary endpoint was change from baseline to 12 months in the motor subscore of the unified Parkinson's disease rating scale in the practically-defined off state. All randomly assigned patients who had at least one assessment after baseline were included in the primary analyses. This trial is registered at ClinicalTrials.gov, NCT00400634. Results Between December, 2006, and November, 2008, 58 patients from nine sites in the USA participated in the trial. There was no significant difference in the primary endpoint in patients treated with AAV2-neurturin compared with control individuals (difference −0·31 [SE 2·63], 95% CI −5·58 to 4·97; p=0·91). Serious adverse events occurred in 13 of 38 patients treated with AAV2-neurturin and four of 20 control individuals. Three patients in the AAV2-neurturin group and two in the sham surgery group developed tumours. Interpretation Intraputaminal AAV2-neurturin is not superior to sham surgery when assessed using the UPDRS motor score at 12 months. However, the possibility of a benefit with additional targeting of the substantia nigra and longer term follow-up should be investigated in further studies. Funding Ceregene and Michael J Fox Foundation for Parkinson's Research." @default.
• W2149731696 created "2016-06-24" @default.
• W2149731696 creator A5003105203 @default.
• W2149731696 creator A5004947713 @default.
• W2149731696 creator A5010956202 @default.
• W2149731696 creator A5011313043 @default.
• W2149731696 creator A5019389906 @default.
• W2149731696 creator A5019667316 @default.
• W2149731696 creator A5024860464 @default.
• W2149731696 creator A5028453258 @default.
• W2149731696 creator A5030324367 @default.
• W2149731696 creator A5032345248 @default.
• W2149731696 creator A5034738574 @default.
• W2149731696 creator A5037361988 @default.
• W2149731696 creator A5042829515 @default.
• W2149731696 creator A5045171549 @default.
• W2149731696 creator A5047447270 @default.
• W2149731696 creator A5053964467 @default.
• W2149731696 creator A5066841660 @default.
• W2149731696 creator A5067906113 @default.
• W2149731696 creator A5068655451 @default.
• W2149731696 creator A5071000356 @default.
• W2149731696 creator A5071124477 @default.
• W2149731696 creator A5073294430 @default.
• W2149731696 creator A5074765508 @default.
• W2149731696 creator A5075350070 @default.
• W2149731696 creator A5084499169 @default.
• W2149731696 creator A5088654646 @default.
• W2149731696 date "2010-12-01" @default.
• W2149731696 modified "2023-10-15" @default.
• W2149731696 title "Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial" @default.
• W2149731696 cites W1970914521 @default.
• W2149731696 cites W1971258758 @default.
• W2149731696 cites W1988111175 @default.
• W2149731696 cites W1989720524 @default.
• W2149731696 cites W1991208841 @default.
• W2149731696 cites W1995724825 @default.
• W2149731696 cites W1996001296 @default.
• W2149731696 cites W1999128801 @default.
• W2149731696 cites W2014571087 @default.
• W2149731696 cites W2019695510 @default.
• W2149731696 cites W2031740174 @default.
• W2149731696 cites W2054810445 @default.
• W2149731696 cites W2056145524 @default.
• W2149731696 cites W2059613352 @default.
• W2149731696 cites W2074890834 @default.
• W2149731696 cites W2086480069 @default.
• W2149731696 cites W2087262420 @default.
• W2149731696 cites W2095401453 @default.
• W2149731696 cites W2103899142 @default.
• W2149731696 cites W2108724455 @default.
• W2149731696 cites W2116993524 @default.
• W2149731696 cites W2117065100 @default.
• W2149731696 cites W2122085123 @default.
• W2149731696 cites W2135907949 @default.
• W2149731696 cites W2138462240 @default.
• W2149731696 cites W2147111512 @default.
• W2149731696 cites W2161558564 @default.
• W2149731696 cites W2161634584 @default.
• W2149731696 cites W2165526364 @default.
• W2149731696 cites W2334461448 @default.
• W2149731696 cites W4292806894 @default.
• W2149731696 doi "https://doi.org/10.1016/s1474-4422(10)70254-4" @default.
• W2149731696 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20970382" @default.
• W2149731696 hasPublicationYear "2010" @default.
• W2149731696 type Work @default.
• W2149731696 sameAs 2149731696 @default.
• W2149731696 citedByCount "560" @default.
• W2149731696 countsByYear W21497316962012 @default.
• W2149731696 countsByYear W21497316962013 @default.
• W2149731696 countsByYear W21497316962014 @default.
• W2149731696 countsByYear W21497316962015 @default.
• W2149731696 countsByYear W21497316962016 @default.
• W2149731696 countsByYear W21497316962017 @default.
• W2149731696 countsByYear W21497316962018 @default.
• W2149731696 countsByYear W21497316962019 @default.
• W2149731696 countsByYear W21497316962020 @default.
• W2149731696 countsByYear W21497316962021 @default.
• W2149731696 countsByYear W21497316962022 @default.
• W2149731696 countsByYear W21497316962023 @default.
• W2149731696 crossrefType "journal-article" @default.
• W2149731696 hasAuthorship W2149731696A5003105203 @default.
• W2149731696 hasAuthorship W2149731696A5004947713 @default.
• W2149731696 hasAuthorship W2149731696A5010956202 @default.
• W2149731696 hasAuthorship W2149731696A5011313043 @default.
• W2149731696 hasAuthorship W2149731696A5019389906 @default.
• W2149731696 hasAuthorship W2149731696A5019667316 @default.
• W2149731696 hasAuthorship W2149731696A5024860464 @default.
• W2149731696 hasAuthorship W2149731696A5028453258 @default.
• W2149731696 hasAuthorship W2149731696A5030324367 @default.
• W2149731696 hasAuthorship W2149731696A5032345248 @default.
• W2149731696 hasAuthorship W2149731696A5034738574 @default.
• W2149731696 hasAuthorship W2149731696A5037361988 @default.
• W2149731696 hasAuthorship W2149731696A5042829515 @default.
• W2149731696 hasAuthorship W2149731696A5045171549 @default.
• W2149731696 hasAuthorship W2149731696A5047447270 @default.
• W2149731696 hasAuthorship W2149731696A5053964467 @default.
• W2149731696 hasAuthorship W2149731696A5066841660 @default.

• next